Protein Family: Enzymes
Pathway and Disease: Cancers, Signaling Molecules and Interaction, Transcription
Description:
The jumonji domain containing 1C protein (JMJD1C) was initially discovered in silico, and later suggested to be a candidate gene for autism. Like the related proteins JMJD1A and JMJD1B, JMJD1C is a histone H3K9 demethylase implicated in the nuclear hormone receptor-based transcriptional regulation. JMJD1C mRNA is highly expressed in undifferentiated embryonic stem (ES) cells as well as pancreatic islet, diffuse-type gastric cancer, and other tissues and tumors. The JMJD1C gene promoter contain bHLH-, AP-1-, and POU5F1-binding sites, and as preferential expression of POU5F1 has been reported in ES cells, pancreatic islet, and diffuse-type gastric cancer, it has been suggested that POU5F1-mediated expression of JMJD1C reactivates previously silenced genes in ES cells and diffuse-type gastric cancer. At least three isoforms of JMJD1C are known to exist. This antibody will not cross-react with JMJD1A or JMJD1B.
Alternate Names: JMJD1C, Jumonji domain containing 1C protein, TRIP8, Probable JmjC domain-containing histone demethylation protein 2C, Thyroid receptor-interacting protein 8, TR-interacting protein 8, TRIP-8, JHDM2C, KIAA1380
Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; IHC: 1:100-1:500; IF: 1:50-1:200
Accession No.: NP_116165
Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human JMJD1C.
Format: Each vial contains 0.1 ml IgG (1 mg/ml) in PBS pH 7.4 with 0.02% sodium azide. Antibody was purified by immunogen affinity chromatography.
Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.